Review article · 2022 · Open access

Real-World Data in the Postapproval Setting as Applied by the EMA and the US FDA

Sarah Mofid, Winona Rei Bolislis, Thomas C. Kühler

Clinical Therapeutics, 44(2), 306–322 · Published 21 January 2022 · DOI 10.1016/j.clinthera.2021.12.010

Open full textCite this paper

In brief

“Real-World Data in the Postapproval Setting as Applied by the EMA and the US FDA” is a 2022 review article by Sarah Mofid and 2 co-authors, published in Clinical Therapeutics. OpenAlex counts 61 citations as of 22 November 2026, which puts it in the top 6% of works published in 2022 by citations. It is open access under a CC BY-NC-ND licence: the full text is free to read at Clinical Therapeutics.

Citations
61
Most cited in
2025 (18)
Field-weighted impact
1.41
References
6
Authors
3

Abstract

PURPOSE: This article provides an analysis of the various regulatory decisions available in the public domain that suggest the use of real-world data (RWD) for postmarketing surveillance activities of products that have a marketing authorization approved by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). The study focuses on the cases in which RWD was used for postapproval commitments or requirements (and to a lesser extent label extensions, as this has been previously published) of medicinal products comprising small molecules and biologics to support efficacy claims or confirm an acceptable safety profile. METHODS: Clarivate Analytics was commissioned to collect data from cases in which RWD was used in the postapproval settings submitted to the EMA (data were found covering the last 14 years) and the FDA (data were found spanning 23 previous years). The query resulted in 165 cases in which regulatory approval was associated with RWD. The data were then categorized and expanded with supporting information gathered from public databases and company websites. FINDINGS: The use of RWD to support regulatory decision-making in the postmarketing surveillance setting has increased in recent years. Most postmarketing surveillance activities are legally enforced requests on the marketing authorization holder to further document the product's safety profile. Data drawn from registries tend to be the most common source in this regard. IMPLICATIONS: RWD have increasingly been used in recent years, both for new product approvals and line extensions and, as shown in this study, in the postapproval setting. There is now a growing appreciation of the potential of RWD as a source in its own right to support regulatory decision-making on the benefits and risks associated with clinical interventions.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Mofid, S., Bolislis, W. R., & Kühler, T. C. (2022). Real-World Data in the Postapproval Setting as Applied by the EMA and the US FDA. Clinical Therapeutics, 44(2), 306–322. https://doi.org/10.1016/j.clinthera.2021.12.010

MLA 9

Mofid, Sarah, et al. “Real-World Data in the Postapproval Setting as Applied by the EMA and the US FDA.” Clinical Therapeutics, vol. 44, no. 2, 2022, pp. 306–322. https://doi.org/10.1016/j.clinthera.2021.12.010.

Chicago

Mofid, Sarah, Winona Rei Bolislis, and Thomas C. Kühler. 2022. “Real-World Data in the Postapproval Setting as Applied by the EMA and the US FDA.” Clinical Therapeutics 44 (2): 306–322. https://doi.org/10.1016/j.clinthera.2021.12.010.

Harvard

Mofid, S., Bolislis, W. R. and Kühler, T. C. (2022) ‘Real-World Data in the Postapproval Setting as Applied by the EMA and the US FDA’, Clinical Therapeutics, 44(2), pp. 306–322. doi:10.1016/j.clinthera.2021.12.010.

IEEE

S. Mofid, W. R. Bolislis, and T. C. Kühler, “Real-World Data in the Postapproval Setting as Applied by the EMA and the US FDA,” Clinical Therapeutics, vol. 44, no. 2, pp. 306–322, 2022, doi: 10.1016/j.clinthera.2021.12.010.

BibTeX

@article{mofid2022real,
  title     = {{Real-World Data in the Postapproval Setting as Applied by the EMA and the US FDA}},
  author    = {Mofid, Sarah and Bolislis, Winona Rei and Kühler, Thomas C.},
  journal   = {Clinical Therapeutics},
  year      = {2022},
  volume    = {44},
  number    = {2},
  pages     = {306--322},
  doi       = {10.1016/j.clinthera.2021.12.010},
  url       = {https://doi.org/10.1016/j.clinthera.2021.12.010}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202233
20231111
20241313
20251818
20261616

Its field-weighted citation impact is 1.41: it has been cited 1.41 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions

  • real-world data
  • post-marketing surveillance
  • regulatory decision-making
  • European Medicines Agency
  • US Food and Drug Administration
  • drug approval
  • registry
  • drug safety

Work with this paper

Most-cited papers in Pharmacology, Toxicology and Pharmaceutics

All highly cited Pharmacology, Toxicology and Pharmaceutics papers

Questions about this paper

How do I cite this paper in APA style?

Mofid, S., Bolislis, W. R., & Kühler, T. C. (2022). Real-World Data in the Postapproval Setting as Applied by the EMA and the US FDA. Clinical Therapeutics, 44(2), 306–322. https://doi.org/10.1016/j.clinthera.2021.12.010

How many times has this paper been cited?

61 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Clinical Therapeutics: sign in and open the full text from this page.

Who wrote this paper?

Sarah Mofid, Winona Rei Bolislis, Thomas C. Kühler.

What is the DOI of this paper?

10.1016/j.clinthera.2021.12.010, permanently at https://doi.org/10.1016/j.clinthera.2021.12.010. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.